ArticleThe Journal of infectious diseases2024
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.
Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- RMF-Activated Superparamagnetic Iron Oxide Nanoparticles Trigger Macrophage-Dependent Protection AgainstInternational journal of molecular sciences · 2026Article
- A Two-Phase Approach to the Use of Tafenoquine Was Associated with Cure of Babesiosis in Two Immunocompromised Patients with Relapsing Babesiosis.Pathogens (Basel, Switzerland) · 2026Article
- Evaluating acridones as novel therapeutics for human babesiosis.Antimicrobial agents and chemotherapy · 2026Article
- Article
- Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi.Parasites & vectors · 2026Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Furamidine, a methyltransferase inhibitor, is a potential anti-Babesia spp. chemotherapeutic.Parasitology research · 2025Article
- Human babesiosis: The past, present and future.Expert reviews in molecular medicine · 2025Review
- Spermidine is a key polyamine required by intracellular parasites for survival within host erythrocytes.Science advances · 2025Article
- Article
- Persistent human babesiosis with low-grade parasitemia, challenges for clinical diagnosis and management.Heliyon · 2024Review
- A set of diagnostic tests for detection of active Babesia duncani infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Article
- Babesia duncani, a Model Organism for Investigating Intraerythrocytic Parasitism and Novel Antiparasitic Therapeutic Strategies.The Journal of infectious diseases · 2024Review
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Article
- Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis.ACS infectious diseases · 2024Article
- New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths.Frontiers in veterinary science · 2024Review
- Case Report: Diagnosis of Hemolytic Anemia from Babesia and Secondary Multi-Pathogen Pneumonia Using a Metagenomic Next-Generation Sequencing Approach.Infection and drug resistance · 2024Article
- Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril.The Journal of biological chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Human babesiosis is a potentially fatal tick-borne disease caused by intraerythrocytic Babesia parasites. The emergence of resistance to recommended therapies highlights the need for new and more effective treatments. Here we demonstrate that the 8-aminoquinoline antimalarial drug tafenoquine inhibits the growth of different Babesia species in vitro, is highly effective against Babesia microti and Babesia duncani in mice and protects animals from lethal infection caused by atovaquone-sensitive and -resistant B. duncani strains. We further show that a combination of tafenoquine and atovaquone achieves cure with no recrudescence in both models of human babesiosis. Interestingly, elimination of B. duncani infection in animals following drug treatment also confers immunity to subsequent challenge. Altogether, the data demonstrate superior efficacy of tafenoquine plus atovaquone combination over current therapies for the treatment of human babesiosis and highlight its potential in providing protective immunity against Babesia following parasite clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.